biote Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.03-14

biote (NASDAQ:BTMD) Full Year 2024 Results

Key Financial Results

  • Revenue: US$197.2m (up 6.4% from FY 2023).
  • Net income: US$3.16m (down 4.8% from FY 2023).
  • Profit margin: 1.6% (down from 1.8% in FY 2023).
  • EPS: US$0.092 (down from US$0.13 in FY 2023).
NasdaqGM:BTMD Revenue and Expenses Breakdown March 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

biote EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 44%.

In the last 12 months, the only revenue segment was Pharmaceuticals contributing US$197.2m. The largest operating expense was General & Administrative costs, amounting to US$107.5m (79% of total expenses). Explore how BTMD's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 27% from a week ago.

Risk Analysis

You still need to take note of risks, for example - biote has 4 warning signs (and 2 which are potentially serious) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment